Iris H. Nelen

Iris H. Nelen

Auto-generated profile, based on publicly available information

Iris H. Nelen

Pediatric Precision Oncology Lab (PPOL), Department of Biomolecular Medicine, Ghent University, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
FSFemmy C. Stempels
Femmy C. Stempels
MJMuwei Jiang
Muwei Jiang
HWHarry M. Warner
Harry M. Warner
MMMagda-Lena Moser
Magda-Lena Moser
MJMaaike H. Janssens
Maaike H. Janssens
Geert van den BogaartGeert van den Bogaart
Geert van den Bogaart
Endosomal Sorting Complex Required for Transport (ESCRT) proteins can be transiently recruited to the plasma membrane for membrane repair and formation of extracellular vesicles. Here, we discovered micrometer-sized worm-shaped ESCRT structures that stably persist for multiple hours at the plasma membrane of macrophages, dendritic cells, and fibroblasts. These structures surround clusters of integrins and known cargoes of extracellular vesicles. The ESCRT structures are tightly connected to the cellular support and are left behind by the cells together with surrounding patches of membrane. The phospholipid composition is altered at the position of the ESCRT structures, and the actin cytoskeleton is locally degraded, which are hallmarks of membrane damage and extracellular vesicle formation. Disruption of actin polymerization increased the formation of the ESCRT structures and cell adhesion. The ESCRT structures were also present at plasma membrane contact sites with membrane-disrupting silica crystals. We propose that the ESCRT proteins are recruited to adhesion-induced membrane tears to induce extracellular shedding of the damaged membrane.

25 February 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
INIris H. Nelen
Iris H. Nelen
SLSoetkin Leys
Soetkin Leys
SBSarah-Lee Bekaert
Sarah-Lee Bekaert
FVFanny De Vloed
Fanny De Vloed
FMFien Martens
Fien Martens
KDKaat Durinck
Kaat Durinck
Tumor cells often cope with elevated levels of replication stress (RS) causing increased dependency on ATR-CHK1 signaling. We previously presented RRM2, the regulatory component of the ribonucleotide reductase (RNR) enzyme, as novel dependency in neuroblastoma (NB), in keeping with its role in RS resistance. We identified strong synergism for combined RRM2-CHK1 inhibition using the iron chelator triapine and prexasertib respectively. To obtain direct RNR targeting, we evaluated a novel inhibitor, TAS1553, specifically disrupting the RNR complex in this study. Treatment with TAS1553 impedes cell growth and induces enhanced RS, DNA damage and apoptosis. We demonstrated strong synergism between TAS1553 and the CHK1 inhibitors prexasertib and SRA737 in both NB cell lines and tumoroids as well as in sarcoma cell lines. We confirm drug synergism in vivo in a NB zebrafish xenograft model, further underscoring the broad clinical potential of combinatorial RRM2-CHK1 inhibition. Altogether, this study paves the way for further preclinical testing of second generation RRM2 and CHK1 inhibitors such as TAS1553 and SRA737 in neuroblastoma and sarcomas.

2 March 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
INIris H. Nelen
Iris H. Nelen
SLSoetkin Leys
Soetkin Leys
SBSarah-Lee Bekaert
Sarah-Lee Bekaert
FVFanny De Vloed
Fanny De Vloed
FMFien Martens
Fien Martens
KDKaat Durinck
Kaat Durinck
Tumor cells often cope with elevated levels of replication stress (RS) causing increased dependency on ATR-CHK1 signalling. We previously presented RRM2, the regulatory component of the ribonucleotide reductase (RNR) enzyme, as novel dependency in neuroblastoma, in keeping with its role in RS resistance. We identified strong synergism for combined RRM2-CHK1 inhibition using the iron chelator triapine and prexasertib respectively. To obtain direct RNR targeting, we evaluated a novel inhibitor, TAS1553, specifically disrupting the RNR complex in this study. Treatment with TAS1553 impedes cell growth and induces enhanced RS, DNA damage and apoptosis. We demonstrated strong synergism between TAS1553 the CHK1 inhibitors prexasertib and SRA737 in both NB and sarcoma cell lines, underscoring the broad clinical potential of combinatorial RRM2-CHK1 inhibition. Transcriptome profiling demonstrated strong overlap between the different RRM2-CHK1 treatments and revealed differential expression of RNA splicing components, opening new perspectives for combination treatments using splicing inhibitors. Altogether, this study paves the way for further preclinical testing of second generation RRM2 and CHK1 inhibitors such as TAS1553 and SRA737 in neuroblastoma and sarcomas.